Phenothiazines Enhance Macrophage Antibacterial Function Through ROS and Autophagy Induction

Study Background and Research Question

Intracellular bacterial infections, caused by pathogens such as Salmonella enterica serovar Typhimurium, Shigella flexneri, Staphylococcus aureus, and Listeria monocytogenes, remain a global health challenge due to their ability to evade traditional antibiotic treatments. The rapid escalation of antimicrobial resistance (AMR) forecasts a scenario where drug-resistant infections may soon become the leading cause of mortality worldwide (Qiu et al., 2025). Conventional antibiotics often fail to eliminate these intracellular pathogens as they are shielded within host cells, highlighting an urgent need for innovative therapeutic strategies. The central research question addressed by Qiu et al. (2025) is whether phenothiazines, a class of compounds best known as antipsychotic drugs and dopamine receptor antagonists, can enhance the intrinsic antibacterial mechanisms of macrophages to combat intracellular bacterial infections (Qiu et al., 2025).

Key Innovation from the Reference Study

The study's principal innovation lies in demonstrating that phenothiazines, including perphenazine, potentiate macrophage antibacterial activity not through direct bacterial killing, but by stimulating host cell defense mechanisms. Specifically, phenothiazine treatment resulted in increased lysosomal activity, pronounced induction of autophagy, and the accumulation of reactive oxygen species (ROS). This host-directed approach represents a paradigm shift from conventional antibiotic therapy, focusing on empowering innate immune cells to control infection (Qiu et al., 2025).

Methods and Experimental Design Insights

Qiu et al. (2025) employed a combination of in vitro and in vivo models to dissect the effects of phenothiazines on macrophage function. The team utilized murine macrophage cultures treated with phenothiazine compounds, systematically measuring:

• Lysosomal enzymatic activity as a marker for phagolysosomal maturation
• Autophagy flux using established autophagy markers
• ROS generation via fluorescence-based assays
• Intracellular bacterial load following infection with S. Typhimurium and other intracellular pathogens

To establish mechanistic causality, the study incorporated co-treatment with autophagy inhibitors and ROS scavengers, enabling robust assessment of the specific pathways involved in phenothiazine-mediated antibacterial effects. In vivo efficacy was further evaluated by assessing organ lesion severity and inflammatory responses in mouse models of S. Typhimurium infection (Qiu et al., 2025).

Protocol Parameters

• cell-based macrophage infection assay | phenothiazine (e.g., perphenazine) 10–100 μM | in vitro assessment of autophagy and ROS induction | dose-dependent effects on macrophage activation and bacterial clearance | paper
• autophagy modulation assay | autophagy inhibitor (e.g., 3-MA) co-treatment | testing autophagy involvement in antibacterial effect | inhibition of phenothiazine-induced bacterial clearance | paper
• ROS quantification assay | ROS scavenger (e.g., NAC) co-treatment | probing ROS role in antibacterial effect | reduction of phenothiazine-induced antibacterial activity with scavenger | paper
• murine infection model | perphenazine dosing regimen (not numerically specified) | in vivo validation of antibacterial protection | decreased organ lesions and inflammation in treated mice | paper

Core Findings and Why They Matter

Three major findings emerged from the study:

1. Phenothiazines potentiate macrophage antibacterial capacity. Macrophages pre-treated with phenothiazines demonstrated enhanced clearance of intracellular bacteria compared to controls (Qiu et al., 2025).
2. Autophagy and ROS are central mediators of this effect. The use of autophagy inhibitors or ROS scavengers markedly reduced the antibacterial activity observed, underscoring that both autophagy induction and ROS accumulation are necessary for the phenothiazine-mediated response.
3. In vivo, phenothiazine treatment mitigates infection severity. Mice infected with S. Typhimurium and treated with perphenazine displayed less severe organ lesions and reduced inflammatory pathology, supporting translational relevance for host-directed therapy (Qiu et al., 2025).

These insights collectively position phenothiazines as promising lead compounds for host-directed antibacterial strategies, with particular relevance to infections involving intracellular pathogens and contexts where antibiotic resistance limits efficacy.

Comparison with Existing Internal Articles

Several internal resources expand the mechanistic and translational context for phenothiazines, particularly Chlorpromazine HCl, a prototypical dopamine receptor antagonist of the phenothiazine class. For example, “Chlorpromazine HCl: Dopamine Receptor Antagonist for Neuroscience and Cell Biology” and “Chlorpromazine HCl: Bridging Mechanistic Insight and Translation” both highlight the compound’s established roles in dopamine receptor inhibition, GABAA receptor modulation, and interference with clathrin-mediated endocytosis, as well as its capacity to shape cellular responses in neuropharmacology studies. While these articles emphasize Chlorpromazine HCl’s contributions to psychotic disorder research and cell biology, the new evidence from Qiu et al. (2025) broadens the utility of phenothiazines to the domain of infectious disease—specifically, as modulators of innate immune cell function. This aligns with prior mechanistic observations on phenothiazine-induced modulation of intracellular pathways, providing a conceptual bridge between neuropharmacological mechanisms and host-pathogen interaction research (internal resource).

Limitations and Transferability

Despite the promising findings, several limitations are noted:

• The study predominantly utilizes murine macrophage models; the translatability of ROS and autophagy induction in human macrophages requires confirmation (Qiu et al., 2025).
• Phenothiazine concentrations effective for immune modulation may approach or overlap with doses affecting neuronal signaling, raising questions about safety and off-target effects in vivo.
• The in vivo experiments focused on organ lesion and inflammation outcomes, but long-term infection resolution and host tolerance were not fully addressed.

Nevertheless, the mechanistic clarity—demonstrating that both autophagy and ROS are required for the observed antibacterial activity—provides a robust basis for further preclinical and translational studies.

Why this cross-domain matters, maturity, and limitations

The extension of phenothiazine pharmacology from neuropsychiatric and cell biology contexts to host-directed antibacterial strategies exemplifies a high-value cross-domain advance. It is supported by mechanistic evidence in both the immune and nervous systems, yet real-world application for infectious diseases will require extensive validation in human models and careful titration to avoid neuropharmacological side effects.

Research Support Resources

Researchers seeking to replicate or extend these findings can access validated phenothiazine compounds such as Chlorpromazine HCl (SKU B1480), which offers robust dopamine receptor antagonism and supports precise dosing in cell-based and in vivo assays (source: product_spec). Detailed solubility and handling guidance are available to facilitate integration into macrophage antibacterial and neuropharmacology studies. For protocol optimization and workflow recommendations, see the referenced internal articles and manufacturer documentation.